{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-23-000116","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2023-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.809239+00:00","generated_at":"2026-06-09T21:50:21.112214+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Caribou Biosciences gets FDA IND clearance for CB-012 allogeneic CAR-T in r/r AML","bullets":["FDA cleared IND for CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for relapsed/refractory AML.","AMpLify Phase 1 trial planned to start patient enrollment by mid-2024; first dose level at 25×10^6 CAR-T cells.","CB-012 is the first allogeneic CAR-T with both PD-1 checkpoint disruption and B2M–HLA-E immune cloaking.","CB-012 is Caribou's third off-the-shelf CAR-T therapy to enter clinical development.","AML has ~20,380 new US cases in 2023; median survival for r/r AML is typically <7 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-23-000116","json":"https://secwatch.observer/filing/0001619856-23-000116.json","markdown":"https://secwatch.observer/filing/0001619856-23-000116.md","text":"https://secwatch.observer/filing/0001619856-23-000116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000116/0001619856-23-000116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000116/crbu-20231018.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T21:50:21.112214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}